Clinical evidence from the STEP trials demonstrated that participants using semaglutide lost between 15 and 22 percent of their starting body weight over approximately one year, though results depend on individual factors including genetics, adherence, and metabolic response
Liposomes are highly versatile and can encapsulate a broad spectrum of molecules: If you're unsure whether your compound is suitable for liposomal delivery, our scientific team will conduct a pre-assessment and recommend the most appropriate strategy
Before starting GLP-1 medications: Ensure you've had a recent diabetic eye screening (within the past 12 months) Discuss your retinopathy status with your prescribing clinician If you have known retinopathy, consider ophthalmology review before initiation Understand that gradual dose titration may help avoid very rapid changes in blood glucose, which is a general principle in diabetes management During treatment: Attend all scheduled diabetic eye screening appointments without fail If you have pre-existing retinopathy, your diabetes team may consider more frequent monitoring based on your individual clinical situation Control blood pressure to target levels (below 140/90 mmHg, or below 130/80 mmHg if you have kidney, eye or cerebrovascular damage, if tolerated) [13] Maintain good overall glycaemic control whilst avoiding excessively rapid HbA1c reductions when possible Stop smoking if applicable, as tobacco significantly worsens diabetic eye disease Manage cholesterol levels according to NICE guidance for cardiovascular risk reduction Communicate openly with your healthcare team about any visual symptoms, even if they seem minor
[1] In experimental models, the peptide appears to influence several pathways involved in healing: angiogenesis, fibroblast migration, collagen organization, nitric oxide signaling, extracellular matrix formation, and reducing inflammatory cytokines
